{
    "Trade/Device Name(s)": [
        "eSensor\u00ae Warfarin Sensitivity Test",
        "eSensor\u00ae XT-8 System"
    ],
    "Submitter Information": "Osmetech Molecular Diagnostics",
    "510(k) Number": "K073720",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ODW",
        "ODV",
        "NSU"
    ],
    "Summary Letter Date": "May 22, 2008",
    "Summary Letter Received Date": "May 27, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3360",
        "21CFR864.7750",
        "21CFR862.2570"
    ],
    "Regulation Name(s)": [
        "Drug Metabolism Enzyme Genotyping Test",
        "Prothrombin Time Test",
        "Instrument for Clinical Multiplex Test Systems"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "hematology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Cytochrome P450 2C9 (CYP2C9*2, CYP2C9*3)",
        "Vitamin K epoxide reductase complex subunit 1 (VKORC1) promoter polymorphism (-1639G>A)"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Genomic DNA"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "eSensor\u00ae XT-8 System"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "PCR amplification"
    ],
    "Methodologies": [
        "Genotyping",
        "Molecular diagnostics",
        "DNA sequencing comparison"
    ],
    "Submission Type(s)": [
        "Assay",
        "Instrument",
        "Kit",
        "Cartridge",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for eSensor\u00ae Warfarin Sensitivity Test and XT-8 System, an in vitro diagnostic for genotyping CYP2C9 and VKORC1 alleles related to warfarin sensitivity.",
    "Indications for Use Summary": "In vitro diagnostic test for detection and genotyping of CYP2C9*2, CYP2C9*3 and VKORC1 promoter polymorphism (-1639G>A) from EDTA-preserved whole blood DNA, aiding identification of patients at risk for increased warfarin sensitivity.",
    "fda_folder": "Toxicology"
}